NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US). Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington (DC): National Academies Press (US); 2012.

Cover of Genome-Based Therapeutics

Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary.

Show details

Appendix AWorkshop Agenda

New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process— A Workshop

March 21, 2012

20 F Street NW Conference Center

20 F Street, NW

Washington, DC 20001

WORKSHOP OBJECTIVES

  • To examine the impact of and investment in the use of genetic and genomic data in drug development.
  • To discuss how genomic and genetic data have been and will be used in the drug development process to improve aspects such as target identification, clinical trial design, pharmacogenomic approaches, biomarker development, and understanding of disease biology.
  • To investigate the economic drivers, incentives, and models for genomic-based strategies for drug development.
8:30–8:35 A.M.WELCOMING REMARKS
Wylie Burke, Roundtable Chair
 Professor and Chair, Department of Bioethics and Humanities, University of Washington
8:35–8:45 A.M.CHARGE TO WORKSHOP SPEAKERS AND PARTICIPANTS
Geoffrey Ginsburg
 Director, Center for Genomic Medicine, Duke University
8:45–10:15 A.M.CURRENT LANDSCAPE
Session Moderator: Aidan Power, Pfizer Inc.
8:45–9:00 A.M.Current Use of Genetic and Genomic Strategies in Drug Development
Nicholas Davies
 Partner, Pharmaceutical and Life Sciences Practice, PwC
9:00–9:15 A.M.Economic Incentives for Genetic and Genomic Strategies
Mark Trusheim
 Visiting Scientist and Executive-in-Residence, MIT Sloan School of Management; President, Co-Bio Consulting
9:15–9:30 A.M.Perceived Challenges in Genomic-Based Drug Development
Garret A. FitzGerald
 Professor of Medicine and Pharmacology and McNeil Professor in Translational Medicine and Therapeutics; Associate Dean for Translational Research; Chair, Department of Pharmacology; Director, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
9:30–10:15 A.M.Discussion with Speakers and Attendees
10:15–10:30 A.M.BREAK
10:30 A.M.– 12:15 P.M.DRUG DISCOVERY AND DEVELOPMENT: CASE STUDIES OF GENOMICS-BASED DRUG DEVELOPMENT
Session Moderator: Michelle Penny, Eli Lilly and Company
10:30–10:50 A.M.Development of Crizotinib for Treatment of Non-Small-Cell Lung Cancer
Steffan N. Ho
 Director, Translational Oncology, Pfizer Inc.
10:50–11:10 A.M.Use of Genetics to Inform Drug Development of a Novel Treatment for Schizophrenia
Laura Nisenbaum
 Senior Research Advisor, Pharmacogenomics, Translational Medicine and Tailored Therapeutics, Eli Lilly and Company
11:10–11:30 A.M.A Genetic Approach to the Treatment of Cystic Fibrosis
Peter Mueller
 Executive Vice President, Global Research and Development; Chief Scientific Officer, Vertex Pharmaceuticals Incorporated
11:30 A.M.– 12:15 P.M.Discussion with Speakers and Attendees
12:15–1:00 P.M.WORKING LUNCH
1:00–2:15 P.M.UTILITY OF EMERGING GENOMICS TECHNOLOGY IN DRUG DEVELOPMENT
Session Moderator: Geoffrey Ginsburg, Duke University
1:00–1:15 P.M.Large-Scale Whole-Genome Sequencing for Disease Understanding, Drug Development, and Genomic Medicine
Radoje Drmanac
 Co-Founder and Chief Scientific Officer, Complete Genomics
1:15–1:30 P.M.Clinical Next Generation Sequencing—Value to Drug Developers
Gary Palmer
 Senior Vice President, Medical Affairs and Commercial Development, Foundation Medicine
1:30–1:45 P.M.Pharma Perspective
Jane Fridlyand
 Senior Statistical Scientist, Genentech
1:45–2:15 P.M.Discussion with Speakers and Attendees
2:15–4:15 P.M.EVOLVING PARADIGMS
Session Moderator: Sharon Terry, Genetic Alliance
2:15–2:30 P.M.Foundations and Drug Development
Walter Capone
 Chief Operating Officer, Multiple Myeloma Research Foundation
2:30–2:45 P.M.Genomics and Regulatory Science
Michael Pacanowski
 Team Leader, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
2:45–3:00 P.M.BREAK
3:00–3:15 P.M.Repurposing of Drugs
Christopher Austin
 Director of the Division of Pre-Clinical Innovation; Scientific Director, NIH Center for Translational Therapeutics; National Center for Advancing Translational Sciences, National Institutes of Health
3:15–3:30 P.M.Pharmacy Benefit Management and Pharmacogenomics
Felix W. Frueh
 President, Medco Research Institute
3:30–4:15 P.M.Discussion with Speakers and Attendees
4:15–5:30 P.M.LEADING THE STRATEGY FOR PERSONALIZED MEDICINE: PHARMA, GOVERNMENT, ACADEMIA— HOW DO WE ALL WORK TOGETHER?
Session Moderator: Thomas Lehner, National Institute of Mental Health, National Institutes of Health
Discussants:
Deborah Dunsire
 President and Chief Executive Officer, Millennium: The Takeda Oncology Company
Victor Dzau
 Chancellor for Health Affairs, Duke University; President and Chief Executive Officer, Duke University Health System
Margaret Hamburg
 Commissioner, U.S. Food and Drug Administration
Kathy Hudson
 Deputy Director for Science, Outreach, and Policy; Acting Deputy Director, National Center for Advancing Translational Sciences, National Institutes of Health
5:30–5:45 P.M.CONCLUDING REMARKS
Geoffrey Ginsburg
 Director, Center for Genomic Medicine, Duke University
5:45 P.M.ADJOURN
Copyright © 2012, National Academy of Sciences.
Bookshelf ID: NBK116447

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...